HeyJaredAbby Proch
- Indexed articles, last 90 days
- 28
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Clinicalleader
- Top 5M sites
- Earliest in this view
- Jul 13, 2026
Latest articles
New Imaging Approach Could Improve IPF Trial Design (opens the original)
Read excerpt
A conversation between Professor Peter George, Ph.D., consultant pulmonologist, and Clinical Leader Executive Editor Abby Proch Timing is everything, as they say. And for diagnostic imaging, the precision and speed with which it’s executed can make all the difference — not only to patients but to researchers. So, what if idiopathic pulmonary fibrosis (IPF) trials could use advancing imaging to spot a treatment effect before traditional lung-function measures do? Pulmonologist Peter George is att
Examining The Potential Of P-tau217 To Provide Earlier Diagnosis Of Alzheimer's (opens the original)
Read excerpt
A conversation between Lilly SVP of Clinical Biomarkers and Diagnostics Nino Sireci, MD, MSc, and Clinical Leader Executive Editor Abby Proch Blood-based biomarkers — particularly P-tau217 — just might reshape Alzheimer’s diagnosis by moving testing from specialized, costly procedures toward a faster, more accessible blood draw. In this Q&A, Lilly’s Nino Sireci, MD, MSc, discusses the current state of early Alzheimer’s diagnosis and the work Lilly’s doing in collaboration with Roche Diagnostics
How VNS-REHAB Aims To Improve Stroke Recovery After Patients Have Plateaued (opens the original)
Read excerpt
A conversation with Brain Recovery Lab, Mass General Brigham University of Health Professions, Lead Investigator, and VNS-REHAB Trial Director Teresa Kimberley, PT, Ph.D., FAPTA, FASNR, and Clinical Leader Executive Editor Abby Proch The potential for recovery plateau after ischemic stroke is a reality for many. The greatest gains occur in the weeks and months after stroke, while meaningful functional limitations may persist long term. Chronic ischemic stroke patients — those who are six months
Repurposing Three FDA-Approved Drugs For A New Stroke Recovery Strategy (opens the original)
Read excerpt
A conversation between Neuro-Innovators CEO Howison Schroeder and Advisory Board Member Ken Phelps and Clinical Leader Executive Editor Abby Proch What do telmisartan, metformin, and cilostazol have in common? They’re already FDA approved drugs. They all have studied neuroplastic properties but might also be a combined pathway to enhance neuroplasticity, says Neuro-Innovators CEO Howison Schroeder. Neuro-Innovators is developing the use of the three drugs as NIV-001, paired with intensive rehabi
Coalition Takes Guesswork Out Of Charcot-Marie-Tooth Disease Research With New Guidance (opens the original)
Read excerpt
A conversation between CMT Research Foundation Chief Mission Officer Susan Ruediger and Clinical Leader Executive Editor Abby Proch Drug developers for Charcot-Marie-Tooth disease used to have a trial design problem. Patient heterogeneity, limited patient population, patient willingness to participate, and variable endpoints have long led to wavering confidence in researchers who were trying to design trials that regulators would accept and patients would agree to. Now, thanks to the work of the
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Clinicalleader, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.